Loading...

SCND

SND

ASCENDIS PHARMA A

(ASND)

2024 6-K

Show Summary

Summary

Warrant Grants

13 Aug '25

Q2 Earnings Report

7 Aug '25

Financial Results Release

7 Aug '25

FDA Approval Announcement

28 Jul '25

Warrant Granting

9 Jul '25

Warrant Exercise Closure

27 Jun '25

Warrant Grants

11 Jun '25

Topline Data Report

9 Jun '25

Clinical Trial Results

9 Jun '25

FDA Acceptance Notification

2 Jun '25

Annual Meeting Outcomes

28 May '25

Warrant Granting

14 May '25

Financial Results Update

1 May '25

Financial Results Q1 2025

1 May '25

Annual Meeting Notice

29 Apr '25

Warrant Grants

9 Apr '25

New Drug Application

31 Mar '25

Warrant Exercise Update

28 Mar '25

IPO Announcement

20 Mar '25

Warrant Grants

12 Mar '25

Share Repurchase Program

12 Feb '25

Financial Results Announcement

12 Feb '25

Warrant Grants Update

12 Feb '25

Warrant Grants

15 Jan '25

Investor Presentation

13 Jan '25

Business Update

13 Jan '25

Warrant Exercise Update

30 Dec '24

Ascendis Collaboration

17 Dec '24

FDA Application Accepted

12 Dec '24

Warrant Granting

11 Dec '24

Quarterly Results

14 Nov '24

Financial Update

14 Nov '24

Warrant Grant Notification

13 Nov '24

Partnership Agreement

4 Nov '24

Warrant Grants

9 Oct '24

FDA Application Submitted

30 Sep '24

Warrant Exercise Closure

27 Sep '24

ADS Offering Summary

23 Sep '24

Trial Results Report

16 Sep '24

Trial Results Report

16 Sep '24

FDA Exclusivity Granted

11 Sep '24

Warrant Grant Details

11 Sep '24

Revenue Participation Agree...

3 Sep '24

Financial Results Report

3 Sep '24

Financial Report Update

3 Sep '24

Warrant Grants

14 Aug '24

FDA Approval Announcement

12 Aug '24

Warrant Grants

10 Jul '24

Warrant Exercise Closed

28 Jun '24

Warrant Grants Report

12 Jun '24

Annual Meeting Results

31 May '24

Warrant Grants

16 May '24

FDA Review Update

14 May '24

Financial Performance Update

2 May '24

Financial Results Report

2 May '24

Annual Meeting Notice

2 May '24

Regulatory Authorization

24 Apr '24

Warrant Grants

10 Apr '24

Warrant Exercises Completed

27 Mar '24

Warrant Grants

14 Mar '24

Management Change

29 Feb '24

Warrant Grants

14 Feb '24

Financial Results Released

7 Feb '24

Product Launch Announcement

31 Jan '24

Company Formation

29 Jan '24

Warrant Grants

10 Jan '24

Investor Meetings Notice

8 Jan '24

Corporate Milestones Update

8 Jan '24

Warrant Exercise Update

2 Jan '24

External Links:

SEC

Ascendis Pharma A/S announced its 2024 corporate milestones and Vision 2030 strategy on January 7, 2024, including projected SKYTROFA revenues of €320-340 million and plans for new drug applications. The filing reveals significant growth plans and ongoing trials for its key products.

AI Assistant

ASCENDIS PHARMA A

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.